Palatin Technologies Inc (NYSE American:PTN)

0.8412
Delayed Data
As of Oct 21
 +0.0089 / +1.07%
Today’s Change
0.59
Today|||52-Week Range
1.78
+18.75%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$189.0M

Company Description

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Contact Information

Palatin Technologies, Inc.
Cedar Brook Corporate Center
Cranbury New Jersey 08512
P:(609) 495-2200
Investor Relations:

Employees

Shareholders

Individual stakeholders9.13%
Other institutional8.28%
Mutual fund holders11.17%

Top Executives

There are no executives to display.